Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

D2850000

Dipyridamole

European Pharmacopoeia (EP) Reference Standard

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C24H40N8O4
Número de CAS:
58-32-2
Peso molecular:
504.63
Número MDL:
MFCD00010555
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329798756
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

dipyridamole

fabricante / nombre comercial

EDQM

mp

165-166 °C (lit.)

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

OCCN(CCO)c1nc(N2CCCCC2)c3nc(nc(N4CCCCC4)c3n1)N(CCO)CCO

InChI

1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2

Clave InChI

IZEKFCXSFNUWAM-UHFFFAOYSA-N

Información sobre el gen

human ... PDE10A(10846) , PDE1A(5136) , PDE1B(5153) , PDE1C(5137) , PDE2A(5138) , PDE3A(5139) , PDE3B(5140) , PDE4A(5141) , PDE4B(5142) , PDE4C(5143) , PDE4D(5144) , PDE5A(8654) , PDE6A(5145) , PDE6B(5158) , PDE6C(5146) , PDE6D(5147) , PDE6G(5148) , PDE6H(5149) , PDE7A(5150) , PDE7B(27115) , PDE8A(5151) , PDE8B(8622) , PDE9A(5152) , SLC29A1(2030)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Dipyridamole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000802

Dipyridamole for peak identification, European Pharmacopoeia (EP) Reference Standard

1220506

Dipyridamole, United States Pharmacopeia (USP) Reference Standard

1220517

Dipyridamole Related Compound A, United States Pharmacopeia (USP) Reference Standard

1220561

Dipyridamole Related Compound F, United States Pharmacopeia (USP) Reference Standard

1220528

Dipyridamole Related Compound B, United States Pharmacopeia (USP) Reference Standard

1220539

Dipyridamole Related Compound C, United States Pharmacopeia (USP) Reference Standard

1220540

Dipyridamole Related Compound D, United States Pharmacopeia (USP) Reference Standard

1220559

Dipyridamole Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP131

Dipyridamole, British Pharmacopoeia (BP) Reference Standard

BP1102

Dipyridamole impurity standard, British Pharmacopoeia (BP) Reference Standard

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Hyung-Hwan Kim et al.
Arteriosclerosis, thrombosis, and vascular biology, 28(3), s39-s42 (2008-01-05)
Dipyridamole (DP) is a phosphodiesterase inhibitor that increases the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanine monophosphate (cGMP) by preventing their conversion to AMP and GMP, respectively. By increasing cAMP and cGMP levels in platelets, DP reversibly
E L L M De Schryver et al.
The Cochrane database of systematic reviews, (2)(2), CD001820-CD001820 (2006-04-21)
Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events (4% to 11% annually). Aspirin reduces that risk by 13%. In one trial, adding dipyridamole to aspirin was associated with a 22% risk-reduction compared with
J Greenhalgh et al.
Health technology assessment (Winchester, England), 15(31), 1-178 (2011-09-06)
Occlusive vascular events such as myocardial infarction (MI), ischaemic stroke and transient ischaemic attack (TIA) are the result of a reduction in blood flow associated with an artery becoming narrow or blocked through atherosclerosis and atherothrombosis. Peripheral arterial disease is
Subrata Chakrabarti et al.
Vascular pharmacology, 48(4-6), 143-149 (2008-03-18)
Stroke is a leading cause of morbidity and mortality and the most common cause of neurological disability in older individuals. Prevention of recurrent stroke includes risk factor modification as well as the use of therapies that inhibit platelet activation. One
Djeven P Deva et al.
Cardiology in the young, 24(5), 822-830 (2013-09-21)
Vasodilator stress perfusion cardiovascular magnetic resonance imaging is a clinically useful tool for detection of clinically significant myocardial ischaemia in adults. We report our 5-year retrospective experience with perfusion cardiovascular magnetic resonance in a large, quarternary adult congenital heart disease
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico